Copyright
©2010 Baishideng.
World J Gastroenterol. Jul 7, 2010; 16(25): 3168-3177
Published online Jul 7, 2010. doi: 10.3748/wjg.v16.i25.3168
Published online Jul 7, 2010. doi: 10.3748/wjg.v16.i25.3168
Demographics | CD | UC |
Total | 179 | 155 |
Age, mean, (SD), [range], yr | 38.9 (± 11.6) [18-71.6] | 39.8 (± 13.7) [18.6-75.5] |
Age at disease onset, mean, (median), [interquartile range], yr | 28 (24.5) [14] | 31.6 (29.2) [16.2] |
Age in males | 28.9 (± 11.7) [12.6-70.7] | 32.6 (± 12.2) [10.3-66.7] |
Age in females | 27.5 (± 12.0) [6.2-72.9] | 30.6 (± 12.6) [11.8-70.6] |
Gender, n (%) | ||
Male | 71 (39.6%) | 71 (45.8%) |
Female | 108 (60.3%) | 84 (54.2%) |
IBD | ||
Disease duration mean, (median), [inter quartile range], yr | 10.9 (9.2) [12.8] | 8.4 (6.7) [9.9] |
Extraintestinal manifestations | ||
Arthralgia | 102 | 79 |
Uveitis | 6 | 2 |
Primary sclerosing cholangitis | 0 | 5 |
Pyoderma gangraenosum | 2 | 3 |
Erythema nodosum | 3 | 0 |
Autoimmune hepatitis | 0 | 1 |
Autoimmune hemolytic anemia | 0 | 1 |
CD-associated polyneuropathy | 1 | - |
Pulmonary manifestations | 1 | 0 |
Current medication (% of users) | ||
Prednisolone | ||
Total | 37.7 | 41.3 |
Systemic | 25.7 | 32.7 |
Local | 13.7 | 11.3 |
Local and systemic | 1.7 | 2.7 |
5-Aminosalicylates | ||
Total | 26.3 | 70.7 |
Local | 1.1 | 3.3 |
Immunosuppressants | ||
Total | 54.9 | 30.0 |
Azathioprine/6-mercaptopurine | 46.9 | 26.4 |
6-MP | 2.9 | 4.0 |
Methotrexate | 2.3 | 1.3 |
Tacrolimus | 0.6 | 4.0 |
TNF-α-inhibitors | 9.1 | 0.7 |
Analgesics | ||
Total | 29.1 | 20.7 |
No information | 25.1 | 32.7 |
Mean IBD severity, mean, (median), [interquartile range] | ||
CDAI | 173 (166) [186] | |
CAI | 5.08 (4.5) [5] | |
SIBDQ, mean, (median), [interquartile range] | 48.3 (49) [21] | 46.7 (47) [21] |
Males | 49.6 (51) [25] | 48.9 (48) [22] |
Females | 47.4 (48) [19] | 44.5 (45) [19] |
SIBDQ healthy controls | 58.5 (59) [10] |
Variable | Mean (95% CI)1 | P value |
Sex | ||
Female | 45.3 (43.0-47.6) | 0.607 |
Male | 46.1 (43.4-48.8) | |
EIM | ||
Yes | 48.1 (46.0-47.7) | 0.004 |
No | 43.3 (40.2-46.4) | |
Pain LUQ | ||
Yes | 44.6 (41.1-48.2) | 0.398 |
No | 46.8 (43.9-50.0) | |
Pain LLQ | ||
Yes | 43.0 (41.0-45.6) | 0.001 |
No | 48.3 (45.6-51.1) | |
Pain RUQ | ||
Yes | 46.5 (43.2-49.8) | 0.511 |
No | 44.8 (41.6-48.1) | |
Pain RLQ | ||
Yes | 45.5 (43.1-47.8) | 0.778 |
No | 45.9 (43.0-48.8) | |
GI-related surgeries | ||
Yes | 46.0 (42.7-49.3) | 0.738 |
No | 45.4 (43.1-47.6) | |
Variable | Regression coefficient estimate2 | P value |
Age (yr) | 0.075 | 0.244 |
IBD duration (mo) | 0.004 | 0.635 |
Pain intensity (0-100 mm)3 | -1.734 | < 0.0001 |
- Citation: Schirbel A, Reichert A, Roll S, Baumgart DC, Büning C, Wittig B, Wiedenmann B, Dignass A, Sturm A. Impact of pain on health-related quality of life in patients with inflammatory bowel disease. World J Gastroenterol 2010; 16(25): 3168-3177
- URL: https://www.wjgnet.com/1007-9327/full/v16/i25/3168.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i25.3168